In this issue:
St Gallen 2013: Consensus on early breast cancer
Non-anthracycline regimen and TOP2A status
Adjuvant bevacizumab: no benefit in triplenegative breast cancer
Patient preference for subcutaneous trastuzumab
Chemoprevention agents for breast cancer risk reduction
Commentary on APBI with breast-conserving surgery
Please login below to download this issue (PDF)